Unlocking Hope for Cancer Patients Using PDT
LEAD CANCER DRUG CANDIDATE INV043
MULTIPLE CANCERS ATTRACTIVE THERAPEUTIC PROFILE
6
Preclinical studies in lead cancer candidate INV043 show:
Effective in regressing multiple types of cancer in vivo
-600x greater photoxicity than Talaporfin (widely
used photosensitiser)
Selectively absorbed by cancer cells and not healthy
tissue
INV043 activity against multiple cancer cell types4
100
80-
60
Viability (% of control)
00
40
20-
Ovarian (SKOV3)
Colorectal (DLD1)
Liver (HEK293)
T-cell Lymphoma (HH).
→ Lung (A549)
Triple Negative Breast
(MDA-MB-468)
Stimulate the body's natural immune response
AI
Work additively with blockbuster ICI¹ drugs
Non-toxic, safe and limited side effects at up to 100x
therapeutic dose
Supporting translation into successful clinical trials²
1 Immune Checkpoint Inhibitor (ICI) therapies are part of the Immunotherapy market
2 Human Ethics submission for first NMSC clinical trial by end of CY2023
4 Studies carried out by Hudson Institute
0.001
0.01
0.1
1
Photosensitizer (μM)
INV043 fluorescing in a tumour under light4
INVIONView entire presentation